UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040919
Receipt number R000046547
Scientific Title Real-time assessment of liver functional reserve in the remnant liver or transplanted graft using indocyanine green pulse spectrophotometry
Date of disclosure of the study information 2020/07/01
Last modified on 2020/06/28 00:06:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Real-time assessment of liver functional reserve in the remnant liver or transplanted graft

Acronym

RTALF trial

Scientific Title

Real-time assessment of liver functional reserve in the remnant liver or transplanted graft using indocyanine green pulse spectrophotometry

Scientific Title:Acronym

ICG-RTALF trial

Region

Japan


Condition

Condition

patients with disease requring hepatectomy or liver transplantation recipient

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Regarding to patients undergoing hepatectomy,aim of the study is to investigate whether the intraoperative ICG clearance value in the future remnant liver could predict post-hepatectomy liver failure. Regarding to transplant recipients, aim of the study is to investigate whether ICG clearance measured during postoperative periods could predict liver graft outcome.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Post-hepatectomy liver failure, defined by ISGLS, for patients undergoing hepatectomy.

Graft failure for transplant recipient

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)patients with hepatectomy(h) performance status, according to the eastern cooperative oncology group criteria of grade 0 or 1
transplant recipients (t) ecog grade 0-3
2) h: child-pugh a or b
t: child-pugh a-c
3) laboratory data (within 14 days before registration)
1.white blood cell >= 2000/ul
2.neutrophil >= 1000/ul
3.hemoglobin >= 9.0g/dl
4.platelet >= 70000/ul
5.total bilirubin >= 2.0mg/dl
6.ast or alt <=150iu/l
7.serum creatine <=1.2mg/dl

Key exclusion criteria

1)patients with allergy to icg
2)patients who underwent hepatectomy with resection of other organs
3) significant medical comorbidity precluding consideration for hepatic surgery.

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Shigeru
Middle name
Last name Marubashi

Organization

Fukushima medical university

Division name

Department of Hepato-Biliary-Pancreatic and Transplant Surgery

Zip code

9601295

Address

1 Hikarigaoka Fukushima

TEL

0245471254

Email

s-maru@fmu.ac.jp


Public contact

Name of contact person

1st name Naoya
Middle name Sato
Last name Sato

Organization

Fukushima medical univerisyt

Division name

Department of Hepato-Biliary-Pancreatic and Transplant Surgery

Zip code

960-1295

Address

1 Hikarigaoka

TEL

0245471254

Homepage URL


Email

nawoya@fmu.ac.jp


Sponsor or person

Institute

Fukushima medical university
Department of Hepato-Biliary-Pancreatic and Transplant surgery

Institute

Department

Personal name



Funding Source

Organization

Fukushima medical university

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Fukushima medical univerity

Address

1 Hikarigaoka Fukushima

Tel

024-547-1111

Email

rs@fmu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2016 Year 06 Month 01 Day

Date of IRB

2016 Year 05 Month 15 Day

Anticipated trial start date

2016 Year 06 Month 01 Day

Last follow-up date

2021 Year 05 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We have planned to perform interim analysis to determine safty and efficacy of ICG monitoring when the number of the registerd patients in greater than 30.


Management information

Registered date

2020 Year 06 Month 28 Day

Last modified on

2020 Year 06 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046547


Research Plan
Registered date File name
2020/06/28 研究計画書.doc

Research case data specifications
Registered date File name

Research case data
Registered date File name
2020/06/28 dataICG.xlsx